US › Healthcare

Pelthos Therapeutics Inc. (PTHS)

US · Healthcare · Biotechnology

$26.70-0.52%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$10.9M

Net profit

$-10.2M

Profit YoY

-420.3%

EPS

$-4.66

EPS estimate

$-3.58

Net margin

-93.9%

EPS came in at -4.66 against a street estimate of -3.58 — a miss of 30.2%.

Key statistics

Market cap

$99.6M

Forward P/E

0.0

P/B

2.84

Book value

$10.42

EPS (TTM)

$-22.92

52-week high

$37.50

52-week low

$16.50

50-day MA

$27.07

200-day MA

$26.17

Beta

3.13

Analyst view

with an average price target of $57.71.

Shareholding

Insiders

53.77%

Institutions

35.63%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pelthos Therapeutics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.